Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors

20024,372 citationsJournal Articlebronze Open Access

Authors

George D. Demetri · Dana-Farber Cancer Institute

Margaret von Mehren · Fox Chase Cancer Center

Charles D. Blanke · Oregon Health & Science University

Annick D. Van den Abbeele · Dana-Farber Cancer Institute

Burton Eisenberg · Fox Chase Cancer Center

Peter Roberts‎ · University of Turku

Michael C. Heinrich

Abstract

Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor. Inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinal stromal tumors, which resist conventional chemotherapy.

Topics & Keywords

Gastrointestinal Tumor Research and Treatment Chronic Myeloid Leukemia Treatments Gastric Cancer Management and Outcomes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 347, Issue 7, pp. 472-480

DOI: 10.1056/nejmoa020461

Field-Weighted Citation Impact: 119.51